Loading…

Active brain changes after initiating fingolimod therapy in multiple sclerosis patients using individual voxel-based analyses for diffusion tensor imaging

Voxel-based analysis (VBA) of diffusion tensor images (DTI) and voxel-based morphometry (VBM) in patients with multiple sclerosis (MS) can sensitively detect occult tissue damage that underlies pathological changes in the brain. In the present study, both at the start of fingolimod and post-four mon...

Full description

Saved in:
Bibliographic Details
Published in:Nagoya journal of medical science 2016-12, Vol.78 (4), p.455-463
Main Authors: Senda, Joe, Watanabe, Hirohisa, Endo, Kuniyuki, Yasui, Keizo, Hawsegawa, Yasuhiro, Yoneyama, Noritaka, Tsuboi, Takashi, Hara, Kazuhiro, Ito, Mizuki, Atsuta, Naoki, Epifanio, Jr, Bagarinao, Katsuno, Masahisa, Naganawa, Shinji, Sobue, Gen
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Voxel-based analysis (VBA) of diffusion tensor images (DTI) and voxel-based morphometry (VBM) in patients with multiple sclerosis (MS) can sensitively detect occult tissue damage that underlies pathological changes in the brain. In the present study, both at the start of fingolimod and post-four months clinical remission, we assessed four patients with MS who were evaluated with VBA of DTI, VBM, and fluid-attenuated inversion recovery (FLAIR). DTI images for all four patients showed widespread areas of increased mean diffusivity (MD) and decreased fractional anisotropy (FA) that were beyond the high-intensity signal areas across images. After four months of continuous fingolimod therapy, DTI abnormalities progressed; in particular, MD was significantly increased, while brain volume and high-intensity signals were unchanged. These findings suggest that VBA of DTI (e.g., MD) may help assess MS demyelination as neuroinflammatory conditions, even though clinical manifestations of MS appear to be in complete remission during fingolimod.
ISSN:0027-7622
2186-3326
DOI:10.18999/nagjms.78.4.455